ACIP Sample Letter
The following is a sample letter to the ACIP incorporating
several important points about the pending vote on the adult
hepatitis B recommendations. It is meant to be used as a guide
for those who wish to submit their own letter to the ACIP.
If you will not be submitting a letter of your own
and would like to sign on to "community" letter,
please contact Dick Conlon at dconlon@TASKFORCE.ORG.
Date
Jon Abramson, MD, Chairman of
ACIP
Weston M. Kelsey Professor & Chair
Department of Pediatrics
Wake Forest University School of Medicine
Email address: jabrams@wfubmc.edu
Larry Pickering, MD,Executive Secretary for ACIP
National Immunization Program/CDC
1600 Clifton Road, NE, Atlanta, GA
Email address: ljp8@cdc.gov
Dear Dr. Abramson and Dr. Pickering:
(I) (We) are writing to request that a final vote on the
draft Recommendations for Adult Hepatitis B Vaccination not
be held at the October 26-27 meeting of the Advisory Committee
on Immunization Practices (ACIP).
The current (9/29/05) ACIP meeting agenda indicates there will
be a discussion of the draft recommendations and a final vote on
October 26. (I am) (We are) concerned that we have not been
given sufficient opportunity to review the current version of the
draft adult hepatitis B vaccination recommendations. As a result,
(I) (we) have been unable to comment on this critical public health
document.
(We) believe a more extensive consultation is vital to our Nation's
public health and request sufficient time to review the recommendations
and provide our consultation. The ACIP agenda, as currently posted
and the process currently underway, does not provide adequate opportunity
for our comments to be provided and considered by ACIP members.
We object to our being denied the opportunity to review the draft
recommendations ahead of time, and to provide our comments for
the Committee’s consideration prior to its voting on the
recommendations.
This ACIP decision will become guiding public health policy in
the US, perhaps for decades to come. It is the first major
change in adult hepatitis B recommendations to be made since 1991,
yet it will be made without sufficient consultation with individuals
and organizations in the public and private sectors that care deeply
about the prevention, control, and treatment hepatitis B in the
United States. Though public comment time is provided on the
current meeting agenda, it will follow the Adult
Hepatitis B decision. Even if the Committee agenda is changed to
provide for public comment prior to the decision, since the draft
is not available for public inspection, there has been no opportunity
to study what is likely to be an extensive – perhaps 40-50
page – draft.
Further, given recent disaster events in the United States, the
diversion of some of our resources to help those affected by hurricanes,
the cost of air travel, and the limited budgets of many groups
engaged in hepatitis B activities, we believe it is unreasonable
to expect representatives from organizations to attend the Committee
meeting as the sole review and public comment opportunity. Therefore,
it is important that ACIP accept written comments during the more
inclusive comment period we are requesting, and that those comments
be considered as important as in-person attendance and that they
are reviewed by all members of the ACIP before a vote is taken.
Hepatitis B is not a trivial infectious disease. Those of us who
work to prevent hepatitis B, who provide care for patients suffering from
acute or chronic stages of hepatitis B, surgeons who perform
transplants, and those who provide care for patients dying from
hepatitis B-caused liver cancer and cirrhosis believe that we have
important contributions to make to the discussion.
We are asking for the opportunity to do so.
Sincerely,
Your organization
cc: Eric
Mast, MD, MPH
Division of Viral Hepatitis/CDC
email address: eem1@cdc.gov
John W. Ward, MD
Division of Viral Hepatitis/CDC
jww4@cdc.gov
Dee Gardner
Staff member, ACIP
National Immunzation Program / CDC
acip@cdc.gov
Mitchell L. Cohen, MD
Director, Coordinating Center for Infectious Diseases/CDC
mlc1@cdc.gov
Julie Gerberding, MD, MPH
Director, CDC
JYG2@cdc.gov
Michael O. Leavitt
Secretary of Health and Human Services
Fax: 202-690-7203
Richard Conlon
Administrator, National Viral Hepatitis Roundtable
dconlon@taskforce.org |